Cargando…

Pichia pastoris-Expressed Bivalent Virus-Like Particulate Vaccine Induces Domain III-Focused Bivalent Neutralizing Antibodies without Antibody-Dependent Enhancement in Vivo

Dengue, a significant public health problem in several countries around the world, is caused by four different serotypes of mosquito-borne dengue viruses (DENV-1, -2, -3, and -4). Antibodies to any one DENV serotype which can protect against homotypic re-infection, do not offer heterotypic cross-pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shukla, Rahul, Rajpoot, Ravi K., Arora, Upasana, Poddar, Ankur, Swaminathan, Sathyamangalam, Khanna, Navin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768101/ https://www.ncbi.nlm.nih.gov/pubmed/29367852 http://dx.doi.org/10.3389/fmicb.2017.02644

Ejemplares similares

Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies
por: Poddar, Ankur, et al.
Publicado: (2016)

Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice
por: Rajpoot, Ravi Kant, et al.
Publicado: (2018)

Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies
por: Tripathi, Lav, et al.
Publicado: (2015)

Pichia pastoris-Expressed Dengue 2 Envelope Forms Virus-Like Particles without Pre-Membrane Protein and Induces High Titer Neutralizing Antibodies
por: Mani, Shailendra, et al.
Publicado: (2013)

Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastoris
por: Schoonooghe, Steve, et al.
Publicado: (2009)

SIGNIFICANCE OF BIVALENCE OF ANTIBODY IN VIRAL NEUTRALIZATION
por: Rosenstein, Robert W., et al.
Publicado: (1971)

Casamino acids facilitate the secretion of recombinant dengue virus serotype-3 envelope domain III in Pichia pastoris
por: Kaushik, Neha, et al.
Publicado: (2016)

A bivalent subunit vaccine efficiently produced in Pichia pastoris against SARS-CoV-2 and emerging variants
por: Xu, Huifang, et al.
Publicado: (2023)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice
por: Ramasamy, Viswanathan, et al.
Publicado: (2018)

Zika virus envelope nanoparticle antibodies protect mice without risk of disease enhancement
por: Shukla, Rahul, et al.
Publicado: (2020)

Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis
por: Liu, Jinny L., et al.
Publicado: (2022)

Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin
por: Gurramkonda, Chandrasekhar, et al.
Publicado: (2010)

Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen
por: Gurramkonda, Chandrasekhar, et al.
Publicado: (2009)

Structural Basis for Recognition of Human Enterovirus 71 by a Bivalent Broadly Neutralizing Monoclonal Antibody
por: Ye, Xiaohua, et al.
Publicado: (2016)

SEROLOGIC DEMONSTRATION OF DUAL SPECIFICITY OF RABBIT BIVALENT HYBRID ANTIBODY
por: Fudenberg, H. H., et al.
Publicado: (1964)

Potent Dengue Virus Neutralization by a Therapeutic Antibody with Low Monovalent Affinity Requires Bivalent Engagement
por: Edeling, Melissa A., et al.
Publicado: (2014)

An orienting response is not enough: Bivalency not infrequency causes the bivalency effect
por: Rey-Mermet, Alodie, et al.
Publicado: (2013)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies
por: Yan, Renhong, et al.
Publicado: (2021)

Structural and functional analysis of an inter-Spike bivalent neutralizing antibody against SARS-CoV-2 variants
por: Li, Yaning, et al.
Publicado: (2022)

Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera
por: Batra, Gaurav, et al.
Publicado: (2011)

Enhanced cell density cultivation and rapid expression-screening of recombinant Pichia pastoris clones in microscale
por: Kaushik, Neha, et al.
Publicado: (2020)

Bivalent Brain Shuttle Increases Antibody Uptake by Monovalent Binding to the Transferrin Receptor
por: Hultqvist, Greta, et al.
Publicado: (2017)

Optical Control of Antibody Activity by Using Photocleavable Bivalent Peptide–DNA Locks
por: Wouters, Simone F. A., et al.
Publicado: (2019)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Optimized Expression and Purification of Humbug in Pichia pastoris and Its Monoclonal Antibody Preparation
por: HUYAN, Ting, et al.
Publicado: (2015)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Bivalent vaccine platform based on Japanese encephalitis virus (JEV) elicits neutralizing antibodies against JEV and hepatitis C virus
por: Saga, Ryohei, et al.
Publicado: (2016)

Recognition of a highly conserved glycoprotein B epitope by a bivalent antibody neutralizing HCMV at a post-attachment step
por: Ye, Xiaohua, et al.
Publicado: (2020)

Binary world/bivalent logic
por: Kittler, Harald
Publicado: (2012)

Bivalent binding on cells varies between anti-CD20 antibodies and is dose-dependent
por: Bondza, Sina, et al.
Publicado: (2020)

Programmable Bivalent Peptide–DNA Locks for pH-Based Control of Antibody Activity
por: Engelen, Wouter, et al.
Publicado: (2019)

SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster
por: Wang, Qian, et al.
Publicado: (2023)

Recombinant Production of Horseradish Peroxidase Conjugates with Fab Antibodies in Pichia pastoris for Analytical Applications
por: Koliasnikov, O.V., et al.
Publicado: (2011)

Design strategy of antidote sequence for bivalent aptamer: Rapid neutralization of high‐anticoagulant thrombin‐binding bivalent DNA aptamer‐linked M08 with HD22
por: Yoshitomi, Toru, et al.
Publicado: (2021)

Use of the Uteroglobin Platform for the Expression of a Bivalent Antibody against Oncofetal Fibronectin in Escherichia coli
por: Ventura, Elisa, et al.
Publicado: (2013)

Bivalent antibody pliers inhibit β-tryptase by an allosteric mechanism dependent on the IgG hinge
por: Maun, Henry R., et al.
Publicado: (2020)

Antibody bivalency improves antiviral efficacy by inhibiting virion release independently of Fc gamma receptors
por: Sahin, Mehmet, et al.
Publicado: (2022)

Bivalent rotavirus VP4∗ stimulates protective antibodies against common genotypes of human rotaviruses
por: Luo, Guoxing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0fded1k87g9b5r50rbc98e0064